Clinical Trial Update: Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of the bispecific PSMAxCD3 antibody CC-1 in squamous cell carcinoma of the lung has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• CC-1 (PSMAxCD3 bispecific antibody)

Snippet

Sponsor: German Cancer Research Center | Conditions: Lung Cancer Squamous Cell | Phase 1, Phase 2 | Status: TERMINATED